ストックスクリーナーアプリを入手
1.19
5.56%
-0.07
アフターアワーズ：
1.22
0.03
+2.52%
前日終値:
$1.26
開ける：
$1.26
24時間の取引高:
459.80K
Relative Volume:
0.80
時価総額：
$64.43M
収益：
-
当期純損益:
$-73.79M
株価収益率:
-0.6467
EPS:
-1.84
ネットキャッシュフロー:
$-77.44M
1週間 パフォーマンス:
+14.42%
1か月 パフォーマンス:
+30.55%
6か月 パフォーマンス:
-69.72%
1年 パフォーマンス:
-72.83%
1日の値動き範囲:
$1.18
$1.30
1週間の範囲:
$0.9901
$1.33
52週間の値動き範囲:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
PYXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.19 | 64.43M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
Renaissance Technologies LLC Acquires 133,018 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology Inc (PYXS) is a good investment, but the stock may be overvalued - uspostnews.com
Taking a look at what insiders are doing to gauge the Pyxis Oncology Inc (PYXS)’s direction - knoxdaily.com
Pyxis Oncology reveals promising preclinical data for cancer drug - Investing.com
Pyxis Oncology reveals promising preclinical data for cancer drug By Investing.com - Investing.com UK
Pyxis Oncology Highlights Promising Preclinical Data for Micvotabart Pelidotin (MICVO) in Cancer Therapy at AACR 2025 - Nasdaq
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC - TradingView
Novel Cancer Drug Shows 91% Tumor Inhibition in Breakthrough Study | PYXS Stock News - Stock Titan
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Pyxis Oncology Inc (PYXS) requires closer examination - uspostnews.com
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms - Yahoo Finance
Pyxis Oncology Inc (PYXS) receives a Mkt perform rating from William Blair - knoxdaily.com
Pyxis Oncology Inc (PYXS) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Top Cancer Stocks to Buy to Boost Your Portfolio's Health - Yahoo Finance
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Sei Investments Co. Acquires New Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
American Century Companies Inc. Has $468,000 Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS) - marketscreener.com
Pyxis Oncology stock plunges to 52-week low of $0.86 - Investing.com Australia
Pyxis Oncology stock plunges to 52-week low of $0.86 By Investing.com - Investing.com UK
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times
CEO Spotlight: Pyxis Oncology to Reveal Latest Cancer Drug Strategy at Elite Stifel Forum - Stock Titan
Pyxis Oncology stock hits 52-week low at $0.98 amid downturn - Investing.com Canada
Is it possible to buy Pyxis Oncology Inc(PYXS) shares at a good price now? - US Post News
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - The Manila Times
Pyxis Oncology to Present Preclinical Data for Micvo Cancer Drug Candidate - MarketScreener
Pyxis Oncology Highlights Strategic Focus on Lead Candidate - TipRanks
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Analysts Set Expectations for Pyxis Oncology Q1 Earnings - Defense World
HC Wainwright Expects Stronger Earnings for Pyxis Oncology - Defense World
Royal Bank of Canada Reiterates Outperform Rating for Pyxis Oncology (NASDAQ:PYXS) - Defense World
Optimistic Buy Rating for Pyxis Oncology Amid Strategic Focus and Promising Drug Developments - TipRanks
HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - Defense World
William Blair Weighs in on Pyxis Oncology FY2027 Earnings - Defense World
Pyxis Oncology’s (PYXS) Buy Rating Reaffirmed at HC Wainwright - The AM Reporter
Pyxis Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RBC Capital Remains a Buy on Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology Advances Cancer Therapeutics with MICVO - TipRanks
Jefferies cuts Pyxis Oncology target to $6, maintains Buy By Investing.com - Investing.com Australia
Jefferies cuts Pyxis Oncology target to $6, maintains Buy - Investing.com India
Pyxis Oncology Announces CMO Resignation and New Trials - TipRanks
Pyxis Oncology, Inc. SEC 10-K Report - TradingView
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Pyxis Oncology Reports Promising Phase 1 Data for MICVO in Head and Neck Cancer, Receives FDA Fast Track Designation - Nasdaq
Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms - Endpoints News
Pyxis Oncology Inc expected to post a loss of 33 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) to Release Earnings on Thursday - Defense World
Closing Figures Unveiled: Pyxis Oncology Inc (PYXS) Drop -2.80, Closes at 1.04 - The Dwinnex
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - The Manila Times
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
3.66%
大文字化:
|
ボリューム (24 時間):